Fibrinogen-coated albumin spheres to speed bone healing in older adults
Official title: Fibrinogen-coated albumin spheres to accelerate bone healing in older adults
Funded at Fibroplate, INC. · NIH-11312001 · Data updated 2026-11-12
A new IV treatment using fibrinogen-coated albumin spheres aims to speed up bone healing in adults aged 65 and older after fractures.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fibroplate, INC. NIH-funded |
| Lab location | 1 site (Las Vegas, United States) |
| Project start | September 23, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,162,390 |
| NIH project number | 1R44AG099306-01 |
| Project ID | NIH-11312001 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults aged 65 and older with acute fractures who are frail or have osteoporosis/osteopenia and can receive intravenous therapy after initial fracture treatment.
✕Less likely to help
Patients who have non-osteoporotic fractures, those unable to receive IV therapy, or those with contraindications to the study product may not benefit.
What this research studies
This project develops an injectable therapy called FPS, based on fibrinogen-coated albumin nano-spheres, to promote faster bone regeneration in frail, elderly patients. It envisions administration shortly after the initial fracture treatment to reach bone marrow stem cells and mobilize repair at the injury site. The approach is designed to be safe for older adults who may not tolerate invasive therapies, with a focus on reducing second injuries and the long-term burden of fractures. The study will follow early development steps to show that FPS can safely accelerate healing in real-world geriatric fracture care.
Why it matters
Potential benefit: If successful, FPS could shorten healing time and reduce complications for fractures in older adults, improving mobility and independence.
How similar studies have gone: Previous work in related biomaterials and fracture healing suggests potential benefits, but this exact FPS approach is novel and requires clinical testing.
Where this research is happening
-
Fibroplate, INC.
Las Vegas, United States Active
Researchers
- Principal investigator: Yen, Richard — Fibroplate, INC.
- Study coordinator: Yen, Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.